Corcept Therapeutics Incorporated

Informe acción NasdaqCM:CORT

Capitalización de mercado: US$2.4b

Salud financiera de hoja de balance de Corcept Therapeutics

Salud financiera controles de criterios 6/6

Corcept Therapeutics tiene un patrimonio de accionistas total de $506.7M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $621.5M y $114.8M respectivamente. El BAIT de Corcept Therapeutics es de $107.3M, por lo que su ratio de cobertura de intereses es de -6.2. Tiene efectivo e inversiones a corto plazo que ascienden a $368.2M.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses-6.2x
EfectivoUS$368.22m
PatrimonioUS$506.71m
Total pasivoUS$114.81m
Activos totalesUS$621.52m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

Apr 15
With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Feb 22
We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Corcept Therapeutics: Key Catalysts Ahead

Feb 19

After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Dec 23
After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Nov 07
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Jun 23
Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Feb 16
Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Jan 11
Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Corcept Therapeutics starts phase 2 trial of its ALS treatment

Oct 11

Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

Sep 27
Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

Corcept extends distribution agreement for Cushing’s syndrome drug

Sep 23

Corcept Therapeutics: A Status Check

Sep 06

Corcept cut to Hold at Truist on balanced risk-reward setup

Aug 01

Corcept Therapeutics begins phase 3 trial of relacorilant for ovarian cancer

Jun 29

I Ran A Stock Scan For Earnings Growth And Corcept Therapeutics (NASDAQ:CORT) Passed With Ease

Jun 09
I Ran A Stock Scan For Earnings Growth And Corcept Therapeutics (NASDAQ:CORT) Passed With Ease

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($458.6M) de CORT superan a sus pasivos a corto plazo ($104.5M).

Pasivo a largo plazo: Los activos a corto plazo de CORT ($458.6M) superan a sus pasivos a largo plazo ($10.3M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: CORT está libre de deudas.

Reducción de la deuda: CORT no tenía deudas hace 5 años.

Cobertura de la deuda: CORT no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.

Cobertura de intereses: CORT no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.


Hoja de balance


Descubre empresas con salud financiera